. 2021 Jan 5;20:199–208. doi: 10.1016/j.omto.2020.12.013

Table 4.

Stratification analysis between YTHDF2 rs3738067 A > G polymorphism and glioma risk

Variables	rs3738067 (cases/controls)		Crude OR	p	AOR (95% CI)^a	p^a
	AA	AG/GG	(95% CI)

Age, months

<60	39/73	46/46	1.87 (1.07–3.29)^b	0.029^b	1.87 (1.06–3.29)^b	0.030^b
≥60	44/71	42/38	1.78 (1.00–3.18)	0.050	1.81 (1.01–3.23)^b	0.046^b

Gender

Females	38/61	43/32	2.16 (1.17–3.97)^b	0.014^b	2.27 (1.22–4.25)^b	0.010^b
Males	45/83	45/52	1.60 (0.93–2.74)	0.089	1.61 (0.93–2.77)	0.087

Subtypes

Astrocytic tumors	61/144	64/84	1.80 (1.16–2.80)^b	0.009^b	1.90 (1.20–2.99)^b	0.006^b
Ependymoma	13/144	12/84	1.58 (0.69–3.63)	0.278	1.58 (0.68–3.64)	0.287
Neuronal and mixed	7/144	7/84	1.71 (0.58–5.06)	0.329	1.63 (0.55–4.84)	0.381
Embryonal tumors	2/144	5/84	4.29 (0.81–22.58)	0.086	6.82 (1.00–46.76)	0.051

Tumor grades

I	52/144	51/84	1.68 (1.05–2.69)^b	0.031^b	1.78 (1.10–2.89)^b	0.018^b
II	14/144	14/84	1.71 (0.78–3.77)	0.180	1.71 (0.78–3.77)	0.182
III	8/144	7/84	1.50 (0.53–4.29)	0.449	1.47 (0.51–4.23)	0.475
IV	9/144	16/84	3.05 (1.29–7.20)^b	0.011^b	3.08 (1.23–7.71)^b	0.016^b
I+II	66/144	65/84	1.69 (1.09–2.61)^b	0.018^b	1.77 (1.14–2.75)^b	0.012^b
III+IV	17/144	23/84	2.32 (1.17–4.59)^b	0.016^b	2.29 (1.14–4.60)^b	0.019^b

AOR, adjusted odds ratio; CI, confidence interval.

Adjusted for age and gender, omitting the corresponding stratify factor.

Significant results.